Normunity has announced a $65 million Series A financing.
Normunity’s new class of agents, called immune normalizers, target previously undiscovered mechanisms of immune disruption in cancer.
The company’s pipeline is drawn from the ongoing and interactive academic-biotech research taking place at Yale School of Medicine, leveraging proprietary discovery platforms from the lab of Dr. Lieping Chen, who identified PD-L1 (B7-H1), among other seminal contributions to the field.